Near Eradication of Clinically Relevant Concentrations of Human Tumor Cells by Interferon-Activated Monocytes In Vitro-Reference-Cited by-同舟云学术

Near Eradication of Clinically Relevant Concentrations of Human Tumor Cells by Interferon-Activated Monocytes In Vitro

Published:2011-07 Issue:7 Volume:31 Page:569-573
ISSN:1079-9907
Container-title:Journal of Interferon & Cytokine Research
language:en
Short-container-title:Journal of Interferon & Cytokine Research

Author:

Baron Samuel¹²,Finbloom Joel¹,Horowitz Julie¹,Bekisz Joseph¹,Morrow Angel¹,Zhao Tongmao¹,Fey Samuel¹,Schmeisser Hana¹,Balinsky Corey¹,Miyake Kotaro¹,Clark Christopher¹,Zoon Kathryn¹

Affiliation:

1. Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

2. University of Texas Medical Branch, Galveston, Texas.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Cell Biology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.2010.0153

Reference34 articles.

1. Clinical Model: Interferons Activate Human Monocytes to An Eradicative Tumor Cell Level In Vitro

2. Antiproliferative Properties of Type I and Type II Interferon

3. Mini ReviewHuman Interferons Alpha, Beta and Omega

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial;Clinical Cancer Research;2022-09-13

2. Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points;Cancers;2021-12-01

3. Monocytes and cancer: promising role as a diagnostic marker and application in therapy;Bulletin of Siberian Medicine;2019-05-16

4. Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer;Immunotherapy;2019-04

5. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer;Journal of Translational Medicine;2018-07-16